Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: The European Organisation for Research and Treatment of Cancer ― Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) studyPENEL, N; GLABBEKE, M. V; DUHAMEL, A et al.British journal of cancer. 2011, Vol 104, Num 10, pp 1544-1550, issn 0007-0920, 7 p.Article

Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic studyGELDERBLOM, H; BLAY, J. Y; MARREAUD, S et al.European journal of cancer (1990). 2014, Vol 50, Num 2, pp 388-396, issn 0959-8049, 9 p.Article

Exatecan in pretreated adult patients with advanced soft tissue sarcoma : Results of a phase II -Study of the EORTC Soft Tissue and Bone Sarcoma GroupREICHARDT, P; NIELSEN, O. S; BLAY, J. Y et al.European journal of cancer (1990). 2007, Vol 43, Num 6, pp 1017-1022, issn 0959-8049, 6 p.Article

Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trialsLE CESNE, A; OUALI, M; BONVALOT, S et al.Annals of oncology. 2014, Vol 25, Num 12, pp 2425-2432, issn 0923-7534, 8 p.Article

Paclitaxel in patients with advanced angiosarcomas of soft tissue : A retrospective study of the EORTC soft tissue and bone sarcoma groupSCHLEMME, M; REICHARDT, P; VERWEIJ, J et al.European journal of cancer (1990). 2008, Vol 44, Num 16, pp 2433-2436, issn 0959-8049, 4 p.Article

Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumoursDE JONGE, M. J. A; DUMEZ, H; VERWEIJ, J et al.European journal of cancer (1990). 2006, Vol 42, Num 12, pp 1768-1774, issn 0959-8049, 7 p.Article

A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancerCLAMP, A. R; SCHOFFSKI, P; JAYSON, G. C et al.Cancer chemotherapy and pharmacology. 2008, Vol 61, Num 4, pp 579-585, issn 0344-5704, 7 p.Article

A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992)THEODORE, C; SKONECZNA, I; BODROGI, I et al.Annals of oncology. 2008, Vol 19, Num 7, pp 1304-1307, issn 0923-7534, 4 p.Article

Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx®) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomasNIELSEN, O. S; REICHARDT, P; CHRISTENSEN, T. B et al.European journal of cancer (1990). 2006, Vol 42, Num 14, pp 2303-2309, issn 0959-8049, 7 p.Article

Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072KASPER, B; SLEIJFER, S; LITIERE, S et al.Annals of oncology. 2014, Vol 25, Num 3, pp 719-724, issn 0923-7534, 6 p.Article

A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)DAUGAARD, G; SKONECZNA, I; SCHMOLL, H. J et al.Annals of oncology. 2011, Vol 22, Num 5, pp 1054-1061, issn 0923-7534, 8 p.Article

Phase i trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development GroupSCHÖFFSKI, P; RIGGERT, S; WILHELM-OGUNBIYI, K et al.Annals of oncology. 2004, Vol 15, Num 12, pp 1816-1824, issn 0923-7534, 9 p.Article

An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for Human Epidermal Growth Factor Receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancerBONNEFOI, H; ZAMAN, K; MARREAUD, S et al.European journal of cancer (1990). 2013, Vol 49, Num 2, pp 281-289, issn 0959-8049, 9 p.Article

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG studySLEIJFER, S; GORLIA, T; HOHENBERGER, P et al.British journal of cancer. 2012, Vol 107, Num 4, pp 639-645, issn 0007-0920, 7 p.Article

Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 yearsPENEL, N; VAN GLABBEKE, M; MARREAUD, S et al.Annals of oncology. 2011, Vol 22, Num 6, pp 1266-1272, issn 0923-7534, 7 p.Article

An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancerCAPONIGRO, F; LACOMBE, D; TWELUES, C et al.European journal of cancer (1990). 2009, Vol 45, Num 1, pp 48-55, issn 0959-8049, 8 p.Article